LGBTQ equality
B (76)
Screens
Advertising
No
Alcohol
No
Animal treatment
Yes
Animal treatment
Yes
Anti-abortion support
Yes
Cannabis
No
Carbon emissions intensity
No
Coal
No
Contraceptives
Yes
Deforestation - financing
No
Deforestation - supply chain
No
Discrimination controversies
No
Environmental controversies
No
Factory farming
No
Fast food
No
Firearms
No
For-profit health care
No
Fossil fuel
No
Fur
No
Gambling
No
Genetic engineering
No
Health-related controversies
No
Human rights controversies
No
Human trafficking
No
Interest-based products
No
Interest-bearing debt
No
Interest-bearing securities
No
Iran
No
Military contracting
No
Misleading communication
No
Music
No
Myanmar
No
Northern Ireland (Macbride)
No
North Korea
No
No SBTI commitment
Yes
Nuclear
No
Oil and gas
No
Opioid controversies
No
Oppressive governments
No
Pharma controversies
Yes
Pork
No
Pornography
No
Predatory lending
No
Prison involvement
No
Privacy breaches
No
Pro-life
No
Russia
Yes
Single-use plastic
No
Stem cell research
Yes
Sudan
No
Sugar
No
Syria
No
Tobacco
No
Undermining US elections
Yes
Weapons
No
Impact

Cause AMGN
Peer rank
LGBTQ equality

Name Rating
Loading...
Screens
Advertising
No
Alcohol
No
Animal treatment
Yes
Animal treatment
Yes
Anti-abortion support
Yes
Cannabis
No
Carbon emissions intensity
No
Coal
No
Contraceptives
Yes
Deforestation - financing
No
Deforestation - supply chain
No
Discrimination controversies
No
Environmental controversies
No
Factory farming
No
Fast food
No
Firearms
No
For-profit health care
No
Fossil fuel
No
Fur
No
Gambling
No
Genetic engineering
No
Health-related controversies
No
Human rights controversies
No
Human trafficking
No
Interest-based products
No
Interest-bearing debt
No
Interest-bearing securities
No
Iran
No
Military contracting
No
Misleading communication
No
Music
No
Myanmar
No
Northern Ireland (Macbride)
No
North Korea
No
No SBTI commitment
Yes
Nuclear
No
Oil and gas
No
Opioid controversies
No
Oppressive governments
No
Pharma controversies
Yes
Pork
No
Pornography
No
Predatory lending
No
Prison involvement
No
Privacy breaches
No
Pro-life
No
Russia
Yes
Single-use plastic
No
Stem cell research
Yes
Sudan
No
Sugar
No
Syria
No
Tobacco
No
Undermining US elections
Yes
Weapons
No
Top metrics
Sample of top metrics driving Amgen's rating for LGBTQ equality (B, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Amgen for LGBTQ equality. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Amgen for LGBTQ equality

...

of potential metrics used

...

unique data

...

peer-average data

5 days ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Amgen. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
AMGN Price
$245.43
Last available end-of-day price. Full disclosure
Revenue
$25.98 billion
Market cap
$127.68 billion
Public/private
Public
Hypothetical growth of $10,000
Historical performance
Company
Founded
1980
Employees
24,200
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Biotechnology
Headquarters
Ca, United States
Share classes
AMGN
Mission
To serve patients. And every step of the way, we are guided by the values that define us.
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Material causes
Ethos considers the following causes material for Amgen, based on its industry peer group Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.